Ultime notizie per Aurora Cannabis (NASDAQ:ACB) Azioni

Aurora Cannabis

Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements.

Aurora Cannabis Inc

Ace Global Business Acquisition Ltd

Ace Global Business Acquisition Ltd Units (1 Ord & 1 War)

Ace Global Business Acquisition Ltd Warrants (26/03/2026)

ALBINA COMMUNITY BNCRP by Albina Community Bancorp

Annabidiol Corp

ARCO BIOMEDICAL CO LTD by Acro Biomedical Co., Ltd.

Acro Biomedical Co Ltd

News

Asset Sales

NOTE

FiscalNote Enters Agreement To Divest Its Australian Subsidiary, TimeBase To Thomson Reuters Corporation For Total Consideration Of $6.5M; Not Withstanding Divestiture Impact, co. Reaffirms 2025 Forecase

Leading diversified professional services and investment management company, Colliers ((NASDAQ, TSX:<a href="https://www.benzinga.com/stock/CIGI#TSX">CIGI</a>), announced today that its Colliers Engineering &amp; Design ("Colliers Engineering") division has acquired Terra Consulting Group, LLC ("Terra"), a specialty telecommunications infrastructure engineering firm based in Chicago, Illinois. This acquisition strengthens Colliers Engineering's footprint in the Midwest and positions the platform to capitalize on the rapid growth in the telecommunications sector. Terms of the transaction were not disclosed.
Founded in 1994, Terra's 70 employees provide telecommunications engineering, land development, site acquisition and structural design services from five offices througout the Midwest region.
"Terra brings deep expertise and relationships in the telecommunications sector, bolstering our existing capabilities and allowing us to further capitalize on the rapid growth in the industry," said Kevin L. Haney, PE, President &amp; CEO, Colliers Engineering. "We are excited to welcome the Terra team to the Colliers family."
"Joining Colliers Engineering &amp; Design will allow us to offer more comprehensive and integrated services to our clients," said John J. Zimmermann, PE, President, Terra. "Colliers' entreprenurial culture and client service focus aligns perfectly with how we operate, and we are confident that joining forces will create many opportunities and continued success for our people."&nbsp;

CIGI

Colliers Announces That Its Colliers Engineering & Design Division Has Acquired Terra Consulting Group; Terms Not Disclosed

TG Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) reported quarterly earnings of $0.03 per share which missed the analyst consensus estimate of $0.17 by 82.35 percent. This is a 142.86 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $120.86 million which beat the analyst consensus estimate of $118.43 million by 2.05 percent. This is a 90.40 percent increase over sales of $63.47 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

TGTX

TG Therapeutics Q1 EPS $0.03 Misses $0.17 Estimate, Sales $120.86M Beat $118.43M Estimate

<ul>
<li>The U.S. FDA has approved SELARSDI&#x2122; (ustekinumab-aekn) as interchangeable with the reference biologic Stelara&#xAE; (ustekinumab) in all presentations matching the reference product, effective as of April 30, 2025</li>
<li>SELARSDI is approved for all indications matching the reference product</li>
<li>SELARSDI is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and pediatric patients 6 years and older, and the treatment of adult patients with moderately to severely active Crohn's disease and ulcerative colitis</li>
</ul>
PARSIPPANY, N.J. and REYKJAVIK, Iceland, May 05, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Alvotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI&#x2122; (ustekinumab-aekn) injection as interchangeable with the reference biologic Stelara&#xAE; (ustekinumab). As of April 30, 2025, SELARSDI is available and interchangeable in all presentations matching the reference product, including the treatment of adults and pediatric psoriatic arthritis and plaque psoriasis, as well as Crohn's disease, and ulcerative colitis.

ALVO

TEVA

Teva Pharma And Alvotech Announce FDA Approval For SELARSDI Injection As Interchangeable With Reference Biologic Stelara

iRadimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRMD#NASDAQ">IRMD</a>) reported quarterly earnings of $0.42 per share which beat the analyst consensus estimate of $0.41 by 2.44 percent. This is a 16.67 percent increase over earnings of $0.36 per share from the same period last year. The company reported quarterly sales of $19.51 million which beat the analyst consensus estimate of $19.33 million by 0.93 percent. This is a 10.87 percent increase over sales of $17.60 million the same period last year.

IRMD

iRadimed Q1 Adj. EPS $0.42 Beats $0.41 Estimate, Sales $19.51M Beat $19.33M Estimate

Chardan Capital analyst Daniil Gataulin maintains Tourmaline Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRML#NASDAQ">TRML</a>) with a Buy and maintains $70 price target.

Price Target

Analyst Ratings

TRML

Chardan Capital Maintains Buy on Tourmaline Bio, Maintains $70 Price Target

NAPCO Security Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSSC#NASDAQ">NSSC</a>) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.27 by 3.7 percent. This is a 22.22 percent decrease over earnings of $0.36 per share from the same period last year. The company reported quarterly sales of $43.96 million which beat the analyst consensus estimate of $43.14 million by 1.91 percent. This is a 10.77 percent decrease over sales of $49.27 million the same period last year.

NSSC

NAPCO Security Techs Q3 GAAP EPS $0.28 Beats $0.27 Estimate, Sales $43.96M Beat $43.14M Estimate

Angel Oak Mortgage REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOMR#NYSE">AOMR</a>) reported quarterly earnings of $0.17 per share which missed the analyst consensus estimate of $0.29 by 41.38 percent. This is a 54.55 percent increase over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $10.09 million which missed the analyst consensus estimate of $11.43 million by 11.76 percent. This is a 17.58 percent increase over sales of $8.58 million the same period last year.

AOMR

Angel Oak Mortgage REIT Q1 Distributable Earnings EPS $0.17 Misses $0.29 Estimate, Sales $10.09M Miss $11.43M Estimate

Billionaire investor Bill Ackman has endorsed &#8220;Buffett &amp; Munger Unscripted,&#8221; a compilation of decades of investment wisdom, calling it &#8220;a great book&#8221; on social media on Sunday.
What Happened: The Pershing Square Capital Management CEO&#8217;s praise comes as Warren Buffett, 94, announced plans to step down as Berkshire Hathaway Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) chief executive by year-end, concluding one of corporate America&#8217;s most celebrated careers.
The book, authored by Alex Morris, presents insights from Buffett and his late business partner, Charlie Munger, through their annual shareholder meetings from 1994 to 2023.
It showcases how the duo transformed Berkshire from a failing textile mill into a conglomerate worth hundreds of billions.
Key investment principles highlighted in the book include opportunity cost evaluation, mental filtering techniques, and skepticism toward modern finance theory.
&#8220;Smart people do very stupid things,&#8221; Buffett is quoted as saying, emphasizing that emotional discipline outweighs raw intelligence.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">This is a great book. <a href="https://t.co/iJyZdTEaVM">https://t.co/iJyZdTEaVM</a>
&mdash; Bill Ackman (@BillAckman) <a href="https://twitter.com/BillAckman/status/1918684001557971163?ref_src=twsrc%5Etfw">May 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/news/25/05/45188098/rep-marjorie-taylor-greene-frustrated-and-upset-with-the-trump-administration-questions-us-foreign-policy-you-better-be-clear-the-base-is-not-happy">Rep. Marjorie Taylor Greene &#8216;Frustrated And Upset&#8217; With The Trump Administration, Questions US Foreign Policy: &#8216;You Better Be Clear, The Base Is Not Happy&#8217;</a>
Why It Matters: The book&#8217;s popularity coincides with Buffett naming Greg Abel as his successor, <a href="https://www.benzinga.com/25/05/45187070/warren-buffett-retires-after-decades-of-dominancefrom-tim-cook-to-mark-cuban-worlds-top-business-leaders-react-to-the-investment-icons-exit">triggering tributes from business leaders</a> worldwide. At Saturday&#8217;s annual meeting in Omaha, Buffett received a standing ovation lasting nearly 10 minutes from thousands of shareholders.
Apple Inc. CEO Tim Cook called it &#8220;one of the great privileges of my life to know him,&#8221; while Microsoft Corp co-founder Bill Gates described Buffett as &#8220;one of the greatest CEOs ever&#8221; and &#8220;hands-down the most successful investor of all time.&#8221;
Despite accumulating a record $348 billion cash reserve, Buffett has maintained his investment philosophy, saying he&#8217;s ready to deploy $20 billion or even $100 billion <a href="https://www.benzinga.com/markets/25/05/45184366/buffett-dismisses-rumors-of-stockpiling-cash-for-successor-greg-abel-i-wouldnt-do-anything-nearly-so-nobl">given the right opportunity</a>. This cash position follows Berkshire&#8217;s sale of two-thirds of its Apple position last year.
Buffett has also signaled unwavering confidence in <a href="https://www.benzinga.com/news/earnings/25/05/45187313/warren-buffett-and-his-successor-greg-abel-say-berkshire-hathaway-could-hold-this-20b-bet-for-50-years-or-forever">Berkshire&#8217;s $20 billion Japanese trading companies</a>, saying, &#8220;In the next 50 years, we won&#8217;t give a thought to selling those positions.&#8221;
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/personal-finance/financial-advisors/25/05/45187836/dave-ramsey-blasts-budget-slackers-who-bail-on-401ks-during-market-turmoil-shortterm-temper-tantrums">Dave Ramsey Blasts Budget Slackers Who Bail On 401(k)s During Market Turmoil: &#8216;Short‑Term Temper Tantrums&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: mark reinstein / Shutterstock.com

Entrepreneurship

Success Stories

Markets

Warren Buffett And Charlie Munger's Timeless Wisdom Draws Bill Ackman's Praise: 'This Is A Great Book'

Management

BRK/A

BRK/B

On May 4, Berkshire's Board Voted To Appoint Greg Abel As President And CEO, Effective Jan. 1, 2026; Warren Buffett To Remain Chairman Of The Board Of Directors

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Buy and maintains $180 price target.

Reiteration

RGEN

HC Wainwright & Co. Reiterates Buy on Repligen, Maintains $180 Price Target

On Friday, May 2nd, U.S. markets closed higher, as strong U.S. jobs data and signs of U.S.-China tariff talks boosted risk appetite. The S&amp;P 500 marked its longest winning streak in over 20 years. While megacap tech stocks cooled, financials and chipmakers outperformed. Treasury yields surged, and European markets closed higher on revived trade hopes.
In economic data, U.S. nonfarm payrolls rose 177,000, beating forecasts and easing tariff worries, while the jobless rate held at 4.2%. March factory orders jumped 4.3% to $618.8 billion.
Most S&amp;P 500 sectors rose Friday, led by financials, communication services, and industrials, while healthcare and consumer staples fell.
The Dow Jones Industrial Average rose 1.39% to 41,317.43, the S&amp;P 500 gained 1.47% to 5,686.67, while the Nasdaq gained 1.51% to 17,977.73.
Asia Markets Today
<ul>
<li>Japan's market closed for the Children's Day holiday.</li>
<li>On Monday, Australia's S&amp;P/ASX 200 declined 0.97%, ending the session at 8,157.80, which was led by losses in the energy, financials, and telecoms services sectors.</li>
<li>India's Nifty 50 was up 0.48% at 24,463.40, and Nifty 500 rose 0.89% to 22,201.65.</li>
<li>China markets closed for the Labour Day holiday.</li>
</ul>
Eurozone at 05:45 AM ET
<ul>
<li>The European STOXX 50 index was down 0.30%.</li>
<li>Germany's DAX index gained 0.60%.</li>
<li>France's CAC 40 slid 0.53%.</li>
<li>The U.K. market closed for the Bank Holiday.</li>
</ul>
Commodities at 05:45 AM ET
<ul>
<li>Crude Oil WTI was trading lower by 1.49% at $57.43/bbl, and Brent was down 1.39% at $60.44/bbl.</li>
<li>Oil prices dropped as OPEC+ agreed to accelerate production hikes, raising concerns about oversupply and weakening demand.</li>
<li>Natural Gas gained 1.60% to $3688.</li>
<li>Gold was trading higher by 2.16% at $3,313.89, Silver was up 1.03% to $32.588, and Copper rose 1.63% to $4.7487.</li>
</ul>
U.S. Futures at 05:45 AM ET
Dow futures were down 0.67%, S&amp;P 500 futures declined 0.78% and Nasdaq 100 futures fell 0.91%.
Forex at 05:45 AM ET
<ul>
<li>The U.S. Dollar Index fell 0.36% to 99.68, USD/JPY was down 0.72% to 143.91, and USD/AUD declined 0.73% to 1.5404.</li>
<li>The U.S. dollar weakened as the Taiwan dollar surged, fueling Asian currency speculation. Despite strong jobs data, Fed rate cut bets shifted to July, while Europe's currencies edged higher.</li>
</ul>
Photo via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia And Europe Markets Mixed, Gold Gains, Oil Slides On OPEC+ Output Hike - Global Markets Today While US Slept

Skeena Resources Limited (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SKE#TSX">SKE</a>)(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKE#NYSE">SKE</a>) ("Skeena Gold and Silver", "Skeena" or the "Company") is pleased to report continued progress on the permitting timeline for its 100%-owned Eskay Creek Gold-Silver Project ("Eskay" or the "Project"). The Company has filed the Joint Permit Application for the BC Mines Act ("MA) and Environmental Management Act ("EMA") with the BC Major Mine Office (MMO) for joint review with the Tahltan Central Government ("TCG"). Uploading of the application started on April 22 and was completed on April 30, 2025.

TSX:SKE

Skeena Resources Files Key Permit Applications for Eskay Creek Project, Partnering with Tahltan Central Government

BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) lowers FY2025 sales outlook from $1.81 billion-$2.35 billion to $1.79 billion-$2.31 billion vs $2.08 billion estimate.

Guidance

BNTX

BioNTech Lowers FY2025 Sales Guidance from $1.81B-$2.35B to $1.79B-$2.31B vs $2.08B Est

International Game Technology PLC ("IGT") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGT#NYSE">IGT</a>) announced today that IGT PlaySports&#x2122; technology is now powering retail sports betting at Silver Reef Casino Resort in Ferndale, Wash. This technology agreement builds on IGT PlaySports' leadership in the region, marking the 11th casino in Washington State to deploy the Company's award-winning sports betting platform, and the 10th casino in the State to leverage its trading advisory services.

IGT Powers Retail Sports Betting at Silver Reef Casino, Expanding Presence in Washington State

BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) reported quarterly losses of $(1.82) per share which beat the analyst consensus estimate of $(2.02) by 9.9 percent. This is a 28.17 percent decrease over losses of $(1.42) per share from the same period last year. The company reported quarterly sales of $192.23 million which beat the analyst consensus estimate of $177.40 million by 8.36 percent. This is a 5.65 percent decrease over sales of $203.74 million the same period last year.

BioNTech Q1 EPS $(1.82) Beats $(2.02) Estimate, Sales $192.23M Beat $177.40M Estimate

HC Wainwright &amp; Co. analyst Robert Burns reiterates ORIC Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORIC#NASDAQ">ORIC</a>) with a Buy and maintains $21 price target.

ORIC

HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $21 Price Target

HC Wainwright &amp; Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLD#NASDAQ">PRLD</a>) with a Buy and maintains $5 price target.

PRLD

HC Wainwright & Co. Reiterates Buy on Prelude Therapeutics, Maintains $5 Price Target

Benchmark analyst David Williams reiterates Belden (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDC#NYSE">BDC</a>) with a Buy and maintains $120 price target.

Benchmark Reiterates Buy on Belden, Maintains $120 Price Target

Stephens &amp; Co. analyst Jim Salera reiterates Wendy's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEN#NASDAQ">WEN</a>) with a Equal-Weight and maintains $14 price target.

Comments

Aurora Cannabis

Notizie

Ultime notizie per Aurora Cannabis (NASDAQ:ACB) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO